HD9665.5 .S45 2015
|
Selling sickness / |
2 |
HD9665.5 .S56
|
Thalidomide and the power of the drug companies / |
1 |
HD9665.5 .S57 2018eb
|
Ghost-managed medicine Big Pharma's invisible hands / |
1 |
HD9665.5 .S578 2013
|
Lean biomanufacturing : creating value through innovative bioprocessing approaches / |
2 |
HD9665.5 .S58 2016
|
The future of pharma : evolutionary threats and opportunities / |
1 |
HD9665.5 .S59 1991
|
Pharmaceutical marketing : strategy and cases / |
1 |
HD9665.5 .S6
|
Principles of pharmaceutical marketing / |
1 |
HD9665.5 .S6 1975
|
Principles of pharmaceutical marketing / |
1 |
HD9665.5 .S64 1990
|
Inside the drug industry / |
2 |
HD9665.5 S658 2016
|
The Future of Pharma : Evolutionary Threats and Opportunities. |
1 |
HD9665.5 .S68 1989
|
Multinational drug companies : issues in drug discovery and development / |
2 |
HD9665.5 .S776 1996
|
Studies in pharmaceutical economics / |
1 |
HD9665.5 .S79 2011eb
|
Venturing into the bioeconomy professions, innovation, identity / |
1 |
HD9665.5 .T34 1993
|
The world pharmaceutical industry / |
1 |
HD9665.5 .T46 2016eb
|
Therapeutic revolutions : pharmaceuticals and social change in the twentieth century / |
1 |
HD9665.5 .T765 2016eb
|
Ema e le relazioni con le big pharma. |
1 |
HD9665.5 .T83 1984
|
The world health market : the future of the pharmaceutical industry / |
2 |
HD9665.5 .T9683 2002eb
|
The 2000-2005 world outlook for OTC healthcare products. |
1 |
HD9665.5 T97 2002eb
|
The 2000-2005 world outlook for prescription. |
1 |
HD9665.5 .U33 2012eb
|
How to commercialise research in biotechnology? effectiveness of the innovation process and of technology transfer in the biotechnology sector / |
1 |